• In January 2026, Manas AI announced a multi-year agreement granting it extensive access to Schrödinger’s physics-based computational drug discovery platform and expert support, aimed at integrating this technology with its AI “world model” for identifying diverse molecular binders.
• A key angle for investors is that Schrödinger’s tools will be tightly embedded into Manas AI’s large-scale discovery workflows, potentially reinforcing Schrödinger’s position in AI-enabled molecular design partnerships.
• We’ll now examine how this deep integration of Schrödinger’s physics-based modeling with Manas AI’s machine learning could shape Schrödinger’s broader investment narrative.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 24 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

What Is Schrödinger's Investment Narrative?

To own Schrödinger, you really have to believe its physics-based software can become a core infrastructure layer for AI-enabled drug and materials discovery, even while the company runs sizeable losses and trades on a rich sales multiple. Near term, software growth and new discovery deals remain the key swing factors, with the recent Manas AI agreement adding a potentially meaningful, if still unquantified, catalyst by embedding Schrödinger’s tools inside a next-generation AI “world model” at ultra-large scale. That kind of integration could strengthen the company’s partnership story, but with financial terms undisclosed and shares still lagging over 1 year and longer, the impact may take time to show up in the numbers. The central risk remains execution: turning technical validation and collaborations into durable, profitable revenue.

However, there is one funding-related risk in particular that investors should not ignore. Despite retreating, Schrödinger's shares might still be trading above their fair value and there could be some more downside. Discover how much.

Exploring Other Perspectives

Six fair value views from the Simply Wall St Community span roughly US$25 to just above US$51, underlining how differently private investors frame Schrödinger’s upside. Set that against the company’s continuing losses and reliance on deal momentum, and it becomes clear why you may want to compare several perspectives before deciding how this story could evolve.

Explore 6 other fair value estimates on Schrödinger - why the stock might be worth over 3x more than the current price!

Build Your Own Schrödinger Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Schrödinger research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Schrödinger research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Schrödinger's overall financial health at a glance.

Want Some Alternatives?

Our top stock finds are flying under the radar-for now. Get in early:

• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• AI is about to change healthcare. These 109 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.